4-(3-羟丙基)苯甲酸乙酯 | 98092-75-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-羟丙基)苯甲酸乙酯
• 英文名称: ethyl 4-(3-hydroxypropyl)benzoate
• CAS: 98092-75-2
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: HXSYDBUGWIEKII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-羟丙基)苯甲酸乙酯 在 吡啶 、 氯化亚砜 作用下， 以 苯 为溶剂， 反应 2.0h， 以91%的产率得到4-(3-氯丙基)苯甲酸乙酯
  参考文献：
  名称：

  7-Substituted 5-Amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A_2A Adenosine Receptor Antagonists:  A Study on the Importance of Modifications at the Side Chain on the Activity and Solubility

  摘要：

  It was demonstrated in the early 1990s that adenosine exerts many physiological functions through the interaction with four different receptors, named A(1), A(2A), A(2B), and A(3). In the past few years, our group has been involved in the development of A(2A) antagonists, which led to the synthesis of SCH 58261 (1), the first potent and selective adenosine A(2A) antagonist, which has been widely used as a reference compound. In this paper, we present an extended series of pyrazolotriazolopyrimidines synthesized with the aim to investigate the influence of the substitutions on the pyrazole ring. The choice of the substituents was based on their capability to improve water solubility while retaining high affinity and selectivity at the human A(2A) adenosine receptor subtype. In this series, some structural characteristics that are important for activity, i.e., tricyclic structure, free amino group at 5-position, furan ring, and substituent at 7-position on the pyrazole moiety, have been maintained. We focused our attention on the nature of the phenyl ring substituent to improve water solubility. Following this strategy, we developed new compounds with good affinity and selectivity for A(2A) adenosine receptors, such as 8d (K-i 0.12 nM; hA(1)/hA(2A) ratio = 1025; R-m = 2.8), 8h (K-i 0.22; hA(1)/hA(2A) ratio = 9818; R-m = 3.4), 8i (K-i 0.18 nM; hA(1)/hA(2A) ratio = 994; R-m = 2.8), 8k (K-i 0.13 nM; hA(1)/hA(2A) ratio = 4430; R-m = 3.6), and 14b (K-i 0.19 nM; hA(1)/hA(2A) ratio = 2273; R-m = 2.7). All the new synthesized compounds have no significant interaction with either-A(2B) or A(3) receptor subtypes. This new series of compounds deeply enlightens some structural requirements to display high affinity and selectivity for the A(2A) adenosine receptor subtype, although our goal of identifying new compounds with increased water solubility was not completely achieved. On this basis, other strategies will be devised to improve this class of compounds with a profile that appears to be promising for treatment of neurodegenerative disorders, such as Parkinson's disease.

  DOI：

  10.1021/jm010924c
• 作为产物：
  描述：

  对乙氧基甲酰苯丙醛 在 sodium tetrahydroborate 、 水 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 以96%的产率得到4-(3-羟丙基)苯甲酸乙酯
  参考文献：
  名称：

  WO2006/63863

  摘要：

  公开号：

文献信息

• Copper-Catalyzed Formal Transfer Hydrogenation/Deuteration of Aryl Alkynes
  作者：Samantha E. Sloane、Albert Reyes、Zoua Pa Vang、Lingzi Li、Kiera T. Behlow、Joseph R. Clark

  DOI：10.1021/acs.orglett.0c03632

  日期：2020.11.20

  A copper-catalyzed reduction of alkynes to alkanes and deuterated alkanes is described under transfer hydrogenation and transfer deuteration conditions. Commercially available alcohols and silanes are used interchangeably with their deuterated analogues as the hydrogen or deuterium sources. Transfer deuteration of terminal and internal aryl alkynes occurs with high levels of deuterium incorporation

  描述了在转移氢化和转移氘化条件下铜催化的炔烃还原为烷烃和氘代烷烃。市售的醇和硅烷与它们的氘代类似物可互换使用，作为氢或氘源。末端和内部芳基炔的转移氘化与氘的高掺入发生。含炔的复杂天然产物类似物以高收率选择性地进行转移氢化和转移氘代。机理实验支持通过顺式烯烃中间体发生的反应，并证明了区域选择性炔烃转移加氢氘代反应的可能性。
• Chemoselective Alkylations with <i>N</i>- and <i>C</i>-Metalated Nitriles
  作者：Xun Yang、Dinesh Nath、Fraser F. Fleming

  DOI：10.1021/acs.orglett.5b02481

  日期：2015.10.2

  electrophilic alkylations. N-Lithiated or C-magnesiated nitriles can be prepared from the same nitrile precursor and selectively reacted with a 1:1 mixture of methyl cyanoformate and benzyl bromide or bifunctional electrophiles through chemoselective attack onto either an alkyl halide or a carbonyl electrophile. A mechanistic explanation for the chemoselectivity preferences is provided that rests on the structural

  金属腈在亲电烷基化中表现出互补的化学选择性。可以从相同的腈前体制备N-锂化或C-镁化的腈，并通过化学选择性攻击烷基卤化物或羰基亲电子试剂，使其与氰基甲酸甲酯和苄基溴或双官能亲电试剂的1：1混合物选择性反应。提供了对化学选择性偏好的机械解释，该解释基于N-和C-金属腈之间的结构和络合差异。
• Iap binding compounds
  申请人：Shi Yigong

  公开号：US20070032437A1

  公开（公告）日：2007-02-08

  Compounds that bind cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, IIid. Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these compounds for therapeutic, diagnostic and assay purposes.

  本文披露了能够结合细胞IAP（凋亡抑制蛋白）的化合物。这些化合物是IAP结合蛋白（如Smac / DIABOLO，IIid Grim和Reaper）N末端四肽的类似物，它们与IAP的特定表面凹槽相互作用。此外，本文还披露了使用这些化合物进行治疗，诊断和检测的方法。
• Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof
  申请人：Diaz Philippe

  公开号：US20080004274A1

  公开（公告）日：2008-01-03

  Novel biaromatic compounds having the general formula (i) below: and cosmetic/pharmaceutical compositions comprised thereof are useful in human or veterinary medicine (in dermatology and also in the fields of cardiovascular diseases, of immune diseases and/or of diseases related to the metabolism of lipids) or, alternatively, in cosmetic compositions.

  具有下列一般式(i)的新型双芳香化合物及其所组成的化妆品/药物组合物在人类或兽医学（在皮肤科以及心血管疾病、免疫疾病和/或与脂质代谢相关的疾病领域）中非常有用，或者在化妆品组合物中使用。
• IAP BINDING COMPOUNDS
  申请人：Shi Yigong

  公开号：US20100261914A1

  公开（公告）日：2010-10-14

  Compounds that bind cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these compounds for therapeutic, diagnostic and assay purposes.

  本发明公开了结合细胞IAP（凋亡抑制蛋白）的化合物。这些化合物是IAP结合蛋白的N-末端四肽的类似物，例如Smac/DIABOLO、Hid、Grim和Reaper，它们与IAP的特定表面凹槽相互作用。还公开了使用这些化合物进行治疗、诊断和测定的方法。